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EDITORIAL
An unexpected role of plasminogen activator inhibitor-type 1
(PAI-1) in renal fibrosis
It has been thought that the profibrotic actions of PAI-
1 are based on inhibition of plasmin generation, which
results in decreased turnover of pathologic matrix. The
data of Oda [1], and Matsuo et al in this issue of Kid-
ney International [2] suggest that PAI-1 may also act by
mechanisms independent of plasmin generation. PAI-1
is the primary inhibitor of tissue-type plasminogen ac-
tivator (tPA) and urokinase-type plasminogen activator
(uPA), molecules that cleave plasminogen to plasmin.
This inhibition decreases both fibrinolysis and matrix
proteolysis. tPA, uPA, and plasmin degrade extracellu-
lar matrix (ECM) proteins, and activate latent matrix
metalloproteinases (MMPs), enzymes that degrade colla-
gens [3]. Decreased PA and plasmin and increased PAI-1
have been reported in many experimental and human
glomerular diseases characterized by mesangial matrix
accumulation [3]. In vitro data first implicated this system
in mesangial matrix turnover when ECM degradation by
cultured mesangial cells (MCs) was shown to be inhibited
by plasmin inhibitors, and addition of a PAI-1 mAb to hu-
man MCs cultured on radioactive matrigel increased ma-
trix degradation fourfold [4]. Plasmin activity and ECM
degradation were greatly reduced in tPA−/tPA− MCs,
and absent in double tPA−/uPA− knock-out MCs [5]. In
vivo data showing that PAI-1 facilitates ECM accumu-
lation used the bleomycin model of pulmonary fibrosis
and demonstrated decreased fibrosis in PAI-1–deficient
and increased fibrosis in PAI-1–overexpressing mice [6].
That this was primarily plasmin-mediated was suggested
when treatment of PAI-1 null mice with the inhibitor of
plasmin formation, tranexamic acid, reversed the protec-
tive effect of PAI-1 deficiency [7]. In the kidney, dou-
ble tPA−/uPA− deficient mice had less plasmin and more
severe crescentic glomerulonephritis [8]. TPA injection
increased plasmin generation and reduced fibrosis in ex-
perimental glomerulonephritis [9]. From these data, it
has been thought that the profibrotic effect of increased
PAI-1 involves limiting plasmin generation and, thereby,
promoting persistence of fibrin deposits and accumula-
tion of fibrotic matrix.
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Recently data have emerged suggesting new mecha-
nisms of PAI-1 action. Interstitial renal fibrosis induced
by unilateral ureteral obstruction was used in PAI-1-
deficient mice by Eddy [1]. It was expected that, as in
the bleomycin model, enhanced plasmin generation in
the absence of PAI-1 would facilitate ECM degrada-
tion and attenuate renal fibrosis. Indeed, PAI-1 deficiency
did reduce collagen content in obstructed kidney. How-
ever, enhanced plasmin activity in PAI-1–deficient kid-
neys was not detected. Although this could be due to
the limitations of the assay employed, it drew attention
to plasmin-independent functions of PAI-1. Since fibro-
sis and cell infiltration were decreased in PAI-1–deficient
mice [1] and increased in the current study using PAI-1–
overexpressing mice [2], the authors suggest that PAI-1
may be profibrotic by enhancing recruitment of fibrosis-
inducing cells independent of its effect to decrease matrix
turnover.
These plasmin-independent functions of PAI-1 may in-
volve PAI-1 binding to vitronectin (Vn), or PAI-1 in-
terference with cell migration or cell binding to matrix.
Through study of tumor invasion, atherosclerosis, throm-
bosis, and vascular biology it has become apparent that
PAI-1, together with uPA and uPA receptor (uPAR), has
dramatic effects on the ability of cells to attach to, mi-
grate on, and detach from their substratum [10]. PAI-1
circulates in plasma bound to Vn. This binding stabi-
lizes PAI-1 in its active conformation, and is reversed
when PAI-1 forms complexes with tPA or uPA. uPA is
secreted as inactive pro-uPA, and is activated by binding
to uPAR on cells. Binding stimulates intracellular signal-
ing and induces conformational changes in uPAR that in-
crease uPAR affinity for Vn and promote its interaction
with a variety of integrins. When PAI-1 then inhibits cell
surface uPA, an inactive PAI-1-uPA-uPAR-integrin com-
plex is formed, cell detachment is initiated, and the com-
plex is rapidly internalized by the low-density lipoprotein
receptor-related protein (LRP). PAI-1 and uPA are de-
graded in lysosomes, while uPAR, integrins, and LRP are
recycled to the cell surface. Thus, PAI-1 binding to cell
surface uPA could promote cell migration simply by dis-
sociating uPAR and integrins from the ECM [10].
PAI-1 binding to Vn may also play a role in cell mi-
gration. PAI-1 binds to Vn with high affinity, while cells
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can attach to Vn through integrins, uPAR, or both. The
Vn binding sites for PAI-1 and uPAR reside in two over-
lapping regions immediately adjacent to the single Arg-
Gly-Asp (RGD) sequence. The affinity of PAI-1 for this
domain is much higher than the affinity of uPAR, and
PAI-1 can competitively inhibit the uPAR-dependent at-
tachment of cells to Vn [11]. PAI-1 binding to Vn also
inhibits integrin-mediated cell adhesion, presumably by
sterically blocking the adjacent RGD site. Thus, PAI-1 is
a member of the class of extracellular proteins termed
‘de-adhesion molecules.’ This property of PAI-1 does not
require plasminogen or the generation of plasmin. Renal
interstitial uPA and PAI-1 are dramatically induced after
ureteral obstruction. Macrophages and tubular epithe-
lial cells express abundant uPAR. Thus, the de-adhesive
properties of PAI-1 may play a role in the recruitment of
macrophages and activation of myofibroblasts in ureteral
obstruction.
Of relevance here are data using a mutant PAI-1 (PAI-
1R) that binds to Vn at the site of fibrosis but does not in-
hibit PAs. Administration of PAI-1R reduces pathologic
matrix accumulation in experimental glomerulonephri-
tis [12]. PAI-1R, with normal Vn affinity but no protease
binding, would be expected to compete with native PAI-
1 and remain bound to Vn longer than native PAI-1,
which is internalized and degraded after protease bind-
ing. While increased plasmin-mediated matrix degrada-
tion is likely to underlie some of PAI-1R’s therapeu-
tic effect, the fact that inflammatory cell infiltration and
mRNA levels for key mediators of fibrosis were reduced
strongly suggest that other mechanisms are involved.
As with many biological molecules, it now appears that
PAI-1 exerts its profibrotic effects by several mechanisms,
both plasmin dependent and plasmin independent.
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